



US006617359B2

(12) **United States Patent**
Wohlfart et al.(10) **Patent No.:** US 6,617,359 B2
(45) **Date of Patent:** Sep. 9, 2003(54) **4-FLUORO-N-INDAN-2-YL BENZAMIDE AND ITS USE AS A PHARMACEUTICAL**(75) Inventors: **Paulus Wohlfart**, Bensheim (DE); **Teri Suzuki**, Tucson, AZ (US); **Ramalinga M. Dharanipragada**, Belle Meade, NJ (US); **Alena Safarova**, Tucson, AR (US); **Armin Walser**, Tucson, AR (US); **Hartmut Strobel**, Liederbach (DE)(73) Assignee: **Aventis Pharma Deutschland GmbH**, Frankfurt am Main (DE)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **10/073,330**(22) Filed: **Feb. 13, 2002**(65) **Prior Publication Data**

US 2003/0022939 A1 Jan. 30, 2003

(30) **Foreign Application Priority Data**

Feb. 13, 2001 (EP) 01102852

(51) **Int. Cl.⁷** **A61K 31/65**(52) **U.S. Cl.** **514/617**(58) **Field of Search** 514/617(56) **References Cited**

FOREIGN PATENT DOCUMENTS

WO	WO 99/47153 A3	9/1999
WO	WO 99/47153 A2	9/1999
WO	WO 00/03746	1/2000
WO	WO 00/51970	9/2000

OTHER PUBLICATIONS

Matthias Endres et al., Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase, Proc. Natl. Acad. Sci. USA, Jul. 1998, vol. 95, pp. 8880-8885.

Huige Li et al., Activation of Protein Kinase C α and/or ϵ Enhances Transcription of the Human Endothelial Nitric Oxide Synthase Gene, Molecular Pharmacology (1998) 53:630-637.

M. F. McCarty, Up-regulation of endothelial nitric oxide activity as a central strategy for prevention of ischemic stroke—Just Say NO to stroke!, Medical Hypotheses (2000) 55(5), 386-403.

Masso Moroi et al., Interaction of Genetic Deficiency of Endothelial Nitric Oxide, Gender, and Pregnancy in Vascular Response to Injury in Mice, The Journal of Clinical Investigation, Mar. 1998, vol. 101, No. 6, 1225-1232.


Masafumi Nakayama et al., T⁻⁷⁸⁶→C Mutation in the 5'-Flanking Region of the Endothelial Nitric Oxide Synthase Gene is Associated With Coronary Spasm, Clinical Investigation and Reports (1999) 2864-2870.

William C. Sessa et al., Chronic Exercise in Dogs Increases Coronary Vascular Nitric Oxide Production and Endothelial Cell Nitric Oxide Synthase Gene Expression, Circulation Research, 1994, vol. 74, No. 2, 349-353.

Olivier Varenne et al., Percutaneous Gene Therapy Using Recombinant Adenoviruses Encoding Human Herpes Simplex Virus Thymidine Kinase, Human PAI-1, and Human NOS3 in Balloon-Injured Porcine Coronary Arteries, Human Gene Therapy (Jun. 10, 2000) 11:1329-1339.

Primary Examiner—Raymond Henley, III(74) *Attorney, Agent, or Firm*—Finnegan, Henderson, Farabow, Garrett and Dunner, L.L.P.(57) **ABSTRACT**

The present invention relates to the method of stimulating the expression of endothelial NO-synthase in a mammal, which method comprises administering a physiologically active amount of 4-fluoro-N-indan-2-yl benzamide according to the formula (I)



to the said mammal. The compound (I) can be used for the therapy and prophylaxis of cardiovascular diseases like stable and unstable angina pectoris, Prinzmetal angina (spasm), acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease PAOD, atherosclerosis, restenosis, endothelial damage after PTCA, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, and the lowering of cardiovascular risk of postmenopausal women or after intake of contraceptives, the therapy and prophylaxis of diabetes and diabetes complications (nephropathy, retinopathy), angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, restricted memory performance or a restricted ability to learn.

27 Claims, No Drawings